Shenzhen Beike Biotechnology Co. Ltd.での幹細胞治療

Founded in 2005, **Shenzhen Beike Biotechnology** is a specialized research organization in Shenzhen, China. The center focuses on adult stem cell research and clinical translation. It manages the entire therapeutic process—from donor selection and cell processing to delivery for clinical use.

National and International Recognitions

The company holds several international quality management certifications:

• ISO 9001 and ISO 17025 certificates
• ISO 45001 and ISO 14001 certificates
• Accreditation from the College of American Pathologists (CAP)
• FDA Drug Master File recognition

Its cell bank meets GMP and AABB standards. In 2011, the Jiangsu Beike inspection center received CNAS accreditation. This made it the first adult stem cell processing laboratory in China to earn this status. Beike is also a member of the **International Society for Cell Therapy (ISCT)**.

Patient Statistics and Research Achievements

The center has treated over 33,500 patients from more than 60 countries. As a research-driven institution, it has published nearly 50 peer-reviewed papers in journals like **Nature**. The company participates in over 60 government projects, including six at the state level. This research directly shapes their stem cell processing and treatment protocols.

Specialized Stem Cell Programs

Beike develops specialized protocols for neurological, neuromuscular, and degenerative conditions. Each treatment cycle combines stem cell transplantation with supportive therapies. The medical team includes specialists such as Dr. Ice, who oversees individualized treatment planning.

Cerebral Palsy Care

The center treats cerebral palsy using a structured two-week protocol. This program pairs stem cell therapy with intensive daily rehabilitation. According to follow-up data from 253 patients:

• 88% reported physical improvement
• 90% reported improved quality of life
• 87% expressed satisfaction with the treatment outcome

Neuromuscular Disorders

The clinic provides specialized care for Duchenne and Becker muscular dystrophy. Specialists use **mesenchymal stem cells (MSCs)** through various administration routes. Registry data shows 85% of these patients reported quality of life improvements. For Spinal Muscular Atrophy, 94% reported improved limb muscle strength.

Integrated Rehabilitation

Every stem cell treatment cycle includes daily multi-modal rehabilitation. These sessions create the right environment for transplanted cells to function. The center offers several supportive therapies:

• Physiotherapy and aquatherapy
• Hyperbaric oxygen therapy
• Transcranial magnetic stimulation (TMS)
• Occupational therapy and acupuncture

Acupuncture helps transmit signals to the brain and spinal cord. This supports pain management and improves nervous system response during recovery.

Verification and Safety Protocols

The center uses a proprietary traceability system for every cell package. This system includes over **900 quality checkpoints**. Lab technicians perform quality checks twice, with one round from an independent laboratory. If a dose fails any checkpoint, it is not released for clinical use.

Every product label features a unique traceability code. Patients and doctors can enter this code into an online verification system. They can then view batch information, quality testing results, and release status in real time. This transparent workflow confirms the safety and origin of every dose.

Services for International Patients

Beike offers coordinated support for patients traveling from outside China. Representatives guide international visitors through each stage of the medical assessment. The center arranges private transportation and provides private room accommodations. Meals are delivered directly to the patient's room during their stay.

Care continues after patients return home through a one-year follow-up program. The medical team sends regular forms via email to track progress. Patients also receive a customized home program to continue supporting the transplanted stem cells.